Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - “DBA/2 is an excellent ...

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a jolt and setting up future registrational trials for the serotonin receptor ...

Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.

LONDON--(BUSINESS WIRE)--The BMB Group, founded in 2006 by members of Asian and Gulf based ruling families, has refocused its business to provide capital and specialist advice exclusively for Forbes ...

Complimentary press passes are now available for Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology (ASBMB). Join us March 23–26 in San Antonio to ...